Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma
出版年份 2020 全文链接
标题
Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma
作者
关键词
-
出版物
CANCER SCIENCE
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2020-06-25
DOI
10.1111/cas.14541
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers
- (2020) Kazuo Okadome et al. BRITISH JOURNAL OF CANCER
- High expression of HLA-DQA1 predicts poor outcome in patients with esophageal squamous cell carcinoma in Northern China
- (2019) Fang-Fang Shen et al. MEDICINE
- Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study.
- (2019) Takashi Kojima et al. JOURNAL OF CLINICAL ONCOLOGY
- KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer
- (2019) Ken Kato et al. Future Oncology
- Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors
- (2019) Yutaka Fujiwara et al. CANCER SCIENCE
- Tumour-associated macrophages are associated with poor prognosis and programmed death ligand 1 expression in oesophageal cancer
- (2019) Taisuke Yagi et al. EUROPEAN JOURNAL OF CANCER
- Impact of tumor-infiltrating LAMP-3 dendritic cells on the prognosis of esophageal squamous cell carcinoma
- (2019) Junya Nishimura et al. Esophagus
- Clinical and molecular predictors of response to immune checkpoint inhibitors in patients with advanced esophagogastric cancer
- (2019) Megan Greally et al. CLINICAL CANCER RESEARCH
- First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1
- (2019) Neeta Somaiah et al. CLINICAL CANCER RESEARCH
- Immune checkpoint inhibitors in esophageal squamous cell carcinoma: progress and opportunities
- (2019) Ruidi Jiao et al. OncoTargets and Therapy
- Morphological lymphocytic reaction, patient prognosis and PD‐1 expression after surgical resection for oesophageal cancer
- (2019) Y. Baba et al. BRITISH JOURNAL OF SURGERY
- Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
- (2019) Ken Kato et al. LANCET ONCOLOGY
- Harnessing NK Cells for Cancer Treatment
- (2019) Paola Minetto et al. Frontiers in Immunology
- Prognostic Role of Tumor-Infiltrating Lymphocytes in Esophagus Cancer: a Meta-Analysis
- (2018) Xiao Zheng et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Safety and Antitumor Activity of the Anti–Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma
- (2018) Toshihiko Doi et al. JOURNAL OF CLINICAL ONCOLOGY
- Implication of Highly Cytotoxic Natural Killer Cells for Esophageal Squamous Cell Carcinoma Treatment
- (2018) Kee Siang Lim et al. JOURNAL OF IMMUNOTHERAPY
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016
- (2018) et al. JAMA Oncology
- CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
- (2018) Yelena Y. Janjigian et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting macrophages: therapeutic approaches in cancer
- (2018) Luca Cassetta et al. NATURE REVIEWS DRUG DISCOVERY
- Precision immunoprofiling by image analysis and artificial intelligence
- (2018) Viktor H. Koelzer et al. VIRCHOWS ARCHIV
- Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus
- (2018) Manish A. Shah et al. JAMA Oncology
- Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status
- (2018) Romain Cohen et al. JAMA Oncology
- Tumor-associated myeloid cells: new understandings on their metabolic regulation and their influence in cancer immunotherapy
- (2017) Chiara Porta et al. FEBS Journal
- Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial
- (2017) Toshihiro Kudo et al. LANCET ONCOLOGY
- Tumour-associated macrophages as treatment targets in oncology
- (2017) Alberto Mantovani et al. Nature Reviews Clinical Oncology
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Myeloid-Derived Suppressor Cells
- (2017) Dmitry I. Gabrilovich Cancer Immunology Research
- PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer
- (2017) Taisuke Yagi et al. ANNALS OF SURGERY
- Biomarkers associated with checkpoint inhibitors
- (2016) G. Manson et al. ANNALS OF ONCOLOGY
- Expression of PD-L1 and HLA Class I in Esophageal Squamous Cell Carcinoma: Prognostic Factors for Patient Outcome
- (2016) Shuhei Ito et al. ANNALS OF SURGICAL ONCOLOGY
- Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling
- (2016) Andy J. Minn et al. CELL
- Microsatellite Instability as a Biomarker for PD-1 Blockade
- (2016) J. C. Dudley et al. CLINICAL CANCER RESEARCH
- Basis for molecular diagnostics and immunotherapy for esophageal cancer
- (2016) Joe Abdo et al. Expert Review of Anticancer Therapy
- Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma
- (2016) Adil I. Daud et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy
- (2016) Geoffrey T Gibney et al. LANCET ONCOLOGY
- Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma
- (2016) Kaiyan Chen et al. Oncotarget
- LV305, a dendritic cell-targeting integration-deficient ZVex TM -based lentiviral vector encoding NY-ESO-1, induces potent anti-tumor immune response
- (2016) Tina Chang Albershardt et al. Molecular Therapy-Oncolytics
- CD38-Expressing Myeloid-Derived Suppressor Cells Promote Tumor Growth in a Murine Model of Esophageal Cancer
- (2015) T. A. Karakasheva et al. CANCER RESEARCH
- Classifying Cancers Based on T-cell Infiltration and PD-L1
- (2015) Michele W.L. Teng et al. CANCER RESEARCH
- PD-1 Blockers
- (2015) Jedd D. Wolchok CELL
- Molecular Pathways: Targeting Tumor-Infiltrating Myeloid-Derived Suppressor Cells for Cancer Therapy
- (2015) D. Di Mitri et al. CLINICAL CANCER RESEARCH
- Nomograms in oncology: more than meets the eye
- (2015) Vinod P Balachandran et al. LANCET ONCOLOGY
- Clinical relevance of host immunity in breast cancer: from TILs to the clinic
- (2015) Peter Savas et al. Nature Reviews Clinical Oncology
- Combination cancer immunotherapies tailored to the tumour microenvironment
- (2015) Mark J. Smyth et al. Nature Reviews Clinical Oncology
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- T cell exclusion, immune privilege, and the tumor microenvironment
- (2015) J. A. Joyce et al. SCIENCE
- Circulating CD14+HLA-DR−/low myeloid-derived suppressor cell is an indicator of poor prognosis in patients with ESCC
- (2015) Haitao Huang et al. TUMOR BIOLOGY
- IL-6-stimulated CD11b+ CD14+ HLA-DR− myeloid-derived suppressor cells, are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus
- (2015) Miao-Fen Chen et al. Oncotarget
- Human leukocyte antigen G is associated with esophageal squamous cell carcinoma progression and poor prognosis
- (2014) Jianyong Zheng et al. IMMUNOLOGY LETTERS
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Esophageal Carcinoma
- (2014) Anil K. Rustgi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor associated macrophage expressing CD204 is associated with tumor aggressiveness of esophageal squamous cell carcinoma
- (2013) Manabu Shigeoka et al. CANCER SCIENCE
- Mutational heterogeneity in cancer and the search for new cancer-associated genes
- (2013) Michael S. Lawrence et al. NATURE
- Alteration of HLA-F and HLA I antigen expression in the tumor is associated with survival in patients with esophageal squamous cell carcinoma
- (2012) X. Zhang et al. INTERNATIONAL JOURNAL OF CANCER
- Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13
- (2011) Rachel F. Gabitass et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma
- (2011) Yoshihiro Komohara et al. CANCER SCIENCE
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review
- (2010) Katsuhiko Nosho et al. JOURNAL OF PATHOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started